AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23036478
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three patches
Trial: 15328674
Drug: Educational handout
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational handout monthly for 2 months
Trial: 3109017
Drug: Enprostil, 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil, 35 micrograms twice daily
Trial: 1972218
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral nicotinamide daily for three weeks
Trial: 1972218
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for three weeks
Trial: 31274492
Drug: Phrenic Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic Nerve Infiltration with 10 mL of 0.2% Ropivacaine
Trial: 31274492
Drug: Paracetamol Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol Infusion with 20mg/kg
Trial: 25873635
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every four weeks (120/Q4W)
Trial: 25873635
Drug: Tabalumab 90
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 90 mg every two weeks (90/Q2W)
Trial: 23567397
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (50-300 mg/day, flexible dosing)
Trial: 11543984
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.35 g/kg)
Trial: 11543984
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.7 g/kg)
Trial: 9631978
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination of bisoprolol/hydrochlorothiazide
Trial: 8161715
Drug: Dilapress 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilapress 120 mg tablets (twice-daily dosing)
Trial: 8161715
Drug: Dilapress 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilapress 240 mg tablets (once-daily treatment)
Trial: 3360860
Drug: Teonova (theophylline)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teonova (theophylline) 600 mg administered 10 min before breakfast
Trial: 3360860
Drug: Teonova (theophylline)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teonova (theophylline) 600 mg administered 60 min after breakfast
Trial: 3360860
Drug: Teonova (theophylline)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teonova (theophylline) 600 mg administered 10 min before dinner
Trial: 3360860
Drug: Teonova (theophylline)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teonova (theophylline) 600 mg administered 60 min after dinner
Trial: 24512252
Drug: 17P (250mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17P (250mg weekly injections)
Trial: 3307889
Drug: Grenz ray
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz ray therapy (3 Gy applied on six occasions at intervals of 1 week)
Trial: 26080572
Drug: Qinghouyan lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinghouyan lozenge for 5 days
Trial: 26080572
Drug: Qinghouyan oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinghouyan oral Liquid for 5 days
Trial: 26080572
Drug: Qinghouyan lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinghouyan lozenge
Trial: 26080572
Drug: Qinghouyan oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinghouyan oral Liquid
Trial: 19553405
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (CJ) 240 mL once daily for 2 weeks
Trial: 19553405
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage 240 mL once daily for 2 weeks
Trial: 11133601
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.75 mg/kg preservative‐free S(+)‐ketamine and 0.75 mg/kg midazolam
Trial: 11133601
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg preservative‐free S(+)‐ketamine
Trial: 9695971
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus 5.0 microg/kg/d MGDF
Trial: 9695971
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus MGDF
Trial: 8205826
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial prophylaxis and sucralfate (1 g/6 hrs)
Trial: 1097878
Drug: Salbutamol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (3 X 2.0 mg)
Trial: 1097878
Drug: Terbutalin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutalin (3 X 2.5 mg)
Trial: 30582281
Drug: Low-dose prolonged-release
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prolonged-release tacrolimus
Trial: 30582281
Drug: Standard-dose prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose prolonged-release tacrolimus
Trial: 30582281
Drug: Low-dose prolonged-release
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prolonged-release tacrolimus + ACEi/ARB
Trial: 30582281
Drug: Low-dose prolonged-release
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prolonged-release tacrolimus + OAHT
Trial: 27906549
Drug: HFHC meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFHC meal with 30 g of insoluble dietary fiber
Trial: 25913272
Drug: RTS,S/AS01 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 with booster dose (R3R group)
Trial: 25913272
Drug: RTS,S/AS01 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 with comparator vaccine (R3C group)
Trial: 25913272
Drug: Comparator vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator vaccine (C3C group)
Trial: 21323490
Drug: Internet cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet cognitive behaviour therapy (CBT)
Trial: 21323490
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behaviour therapy (CBT)
Trial: 19776082
Drug: Electrocautery dissection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrocautery dissection and application of a collagen patch coated with human fibrinogen and thrombin (TachoSil)
Trial: 19776082
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) with stapling device
Trial: 14742372
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream after ultrasound pretreatment
Trial: 14742372
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream application for 5 min
Trial: 14742372
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream application for 10 min
Trial: 14742372
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream application for 15 min
Trial: 14742372
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream application for 60 min without ultrasound pretreatment
Trial: 9148253
Drug: Timolol hydrogel
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol hydrogel (T-Gel 0.1%)
Trial: 26411031
Drug: CQR-300, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQR-300, 300 mg daily
Trial: 18829797
Drug: Higher rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher rates of infusion of intravenous fat emulsion
Trial: 16060411
Drug: manidipine 20
RxNorm normalized name: manidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manidipine 20 mg o.d. for 4 weeks
Trial: 16060411
Drug: delapril 30
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delapril 30 mg b.i.d. for 4 weeks
Trial: 16060411
Drug: fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed combination of manidipine 10 mg plus delapril 30 mg o.d. for 8 weeks
Trial: 12403690
Drug: Montelukast and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast and Budesonide (combination)
Trial: 10879210
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment services
Trial: 31126327
Drug: Siblings (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siblings (treatment with benznidazole)
Trial: 18693600
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg per day)
Trial: 15151516
Drug: Fexofenadine (FEX)
RxNorm normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine (FEX) 180 mg + Montelukast (ML) 10 mg
Trial: 8228340
Drug: High-titer vaccine
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer vaccine (100-fold greater than standard titer)
Trial: 8228340
Drug: Medium-titer vaccine
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-titer vaccine (10-fold greater than standard titer)
Trial: 3803483
Drug: Preparation interval
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation interval prior to verbal and spatial tasks
Trial: 23682661
Drug: GSK2190915 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 30 mg QD
Trial: 20181971
Drug: Integrated antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated antiretroviral therapy during tuberculosis therapy (combined integrated-therapy groups)
Trial: 20181971
Drug: Sequential antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antiretroviral therapy after completion of tuberculosis therapy (sequential-therapy group)
Trial: 17997391
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g)
Trial: 11078178
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 to 10 mg twice a day
Trial: 11078178
Drug: Enalapril 2.5
RxNorm normalized name: enalapril 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5 to 20 mg twice a day
Trial: 8712033
Drug: Neuroleptic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic medication (doses above 2000 mg chlorpromazine equivalents daily)
Trial: 1281062
Drug: Subcutaneous salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous salmon calcitonin (100 U Calcitonin Sandoz) for 21 days plus physical treatment and early mobilization
Trial: 28922338
Drug: Esmolol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.7 mg/kg bolus over 1 min followed by infusion at 10 μg/kg/min)
Trial: 28922338
Drug: Remifentanil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.2 μg/kg/min infusion)
Trial: 24942382
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg every 4 weeks (Q4W)
Trial: 24013647
Drug: Combined CZP
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CZP arms (200 mg Q2W and 400 mg Q4W)
Trial: 12468560
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg daily
Trial: 8222743
Drug: Standard adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adhesive tape treatment
Trial: 3518772
Drug: Fenclofenac at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenclofenac at 600 mg day-1
Trial: 3518772
Drug: Fenclofenac at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenclofenac at 1200 mg day-1
Trial: 3518772
Drug: Fenclofenac at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenclofenac at 1800 mg day-1
Trial: 30286820
Drug: Policosanol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol (20 mg/day)
Trial: 26626320
Drug: Rotigotine (optimal/maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (optimal/maximum dose <16 mg/24h)
Trial: 24185607
Drug: Patient-controlled levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled levobupivacaine 1.25 mg/ml via i.p. catheter as needed (maximum once per hour) with continuous saline infusion 10 ml/h
Trial: 24185607
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of levobupivacaine 1.25 mg/ml 10 ml/h and bolus saline as needed
Trial: 24185607
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of levobupivacaine
Trial: 17725600
Drug: Lansoprazole (proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (proton pump inhibitor) for 4 weeks
Trial: 12416946
Drug: Leflunomide added
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide added to existing methotrexate therapy
Trial: 12416946
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to existing methotrexate therapy
Trial: 10628925
Drug: Postal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postal administration with financial incentive
Trial: 10628925
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration with financial incentive
Trial: 10628925
Drug: Clinic visit
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic visit administration with financial incentive
Trial: 10628925
Drug: Postal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postal administration without financial incentive
Trial: 10628925
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration without financial incentive
Trial: 10628925
Drug: Clinic visit
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic visit administration without financial incentive
Trial: 8845402
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral acyclovir (ACV)
Trial: 1775083
Drug: Intranasal spray
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray (4 doses of an oil‐based P solution at a concentration of 2 mg/0.1 ml, total dose approximately 11 mg of P)
Trial: 1775083
Drug: Ointment (quantity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment (quantity 0.1 ml, P concentration 20 mg/0.1 ml)
Trial: 7068938
Drug: Diflunisal (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (all doses)
Trial: 25524950
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered in the evening (2200 h)
Trial: 25524950
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered in the morning (1000 h)
Trial: 19300303
Drug: Stable isotope‐labelled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable isotope‐labelled nicotine infusion
Trial: 9341413
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose solution during the first 3 days of life in addition to being breastfed
Trial: 8428871
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 5, 10, 15, and 20 mg
Trial: 25790328
Drug: Resveratrol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (150 mg per day)
Trial: 21936938
Drug: High-energy protein
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy protein supplement (HEPS)
Trial: 15164887
Drug: Caffeine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (0.3 mg per kg per hour)
Trial: 14673617
Drug: GaAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAs laser treatment applied over three trigger points bilaterally and one point in the taut bands in trapezius muscle bilaterally with a frequency of 1000 Hz for 2 min over each point once a day for 10 days during a period of 2 weeks
Trial: 14673617
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (laser instrument switched off) with the same treatment protocol
Trial: 31048013
Drug: Cyclosporine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (4 mg/kg/d)
Trial: 28507108
Drug: ABX464 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (up to 150 mg once a day)
Trial: 26644127
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy (CIMT) combined with motor and sensory‐motor interventions
Trial: 26644127
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care occupational and physical therapy
Trial: 21748303
Drug: After administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After administration of a proton pump inhibitor
Trial: 19922603
Drug: Postural exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postural exercise therapy
Trial: 16508401
Drug: Ketamine (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.24 mg/kg)
Trial: 14987306
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily
Trial: 14720267
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray 220 microg once daily
Trial: 14720267
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray
Trial: 9313671
Drug: Spermatic-cord block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermatic-cord block (10 mL of 0.5% plain bupivacaine)
Trial: 9313671
Drug: Conventional analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesic regimen (general anaesthesia, fentanyl, and diclofenac)
Trial: 8370132
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (10 mg) administered 60 minutes prior to GHRH (100 micrograms i.v. bolus)
Trial: 8370132
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (10 mg) administered 60 minutes prior to a submaximal dose (3 micrograms i.v. bolus) of GHRH
Trial: 8370132
Drug: Oral pyridostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pyridostigmine (120 mg)
Trial: 8370132
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of melatonin (10 mg) and pyridostigmine (120 mg)
Trial: 3011310
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nedocromil sodium